Platin-DRP™
The world’s only validated predictor for platinum treatment response
Clinically proven in breast and lung cancers to identify patients most likely to benefit from platinum therapy
— with expansion into immunotherapy combinations underway.
Our unique
The Platin-DRP™ is a multigene mRNA-based algorithm originally developed using the Drug Response Predictor (DRP®) platform. It predicts a patient’s likely response to platinum-based chemotherapy. We believe our companion diagnostic will significantly improve cancer patient outcomes by tailoring treatment based on individual tumor biology. Platin-DRP™ has consistently demonstrated its ability to identify which patients are most likely to benefit from platinum treatment and which are not, enabling clinicians to avoid overtreating non-responders with platinum-based treatments, sparing them unnecessary side effects and reducing delays in starting more effective therapies.
advantage lies
in our patented
DRP® technology.
From Tumor Biology to Patient Benefit — How DRP® Works
A simple test predicts whether a patient is likely to respond to platinum therapy, using the tumor’s gene expression profile.
The Only Proven Biomarker For Cisplatin
The Platin-DRP™ is a multigene mRNA-based algorithm that uses the 205 licensed genes relating to cisplatin and carboplatin sensitivity and resistance. The technology is built upon a deep systems biology analysis of all transcriptional changes in tumor cells in response to a broad range of drug types including cisplatin and carboplatin. CHOSA has refined the Platin-DRP™ algorithm with actual gene expression data with tumors from over 3,000 patients, proving its clinical relevance.
The Platin-DRP™ uses the already available biopsy from the pathologist for its own analysis of the tumor gene expression. The Platin-DRP™ prediction is based on the correlation between the tumor's gene expression profile and known response patterns to cisplatin regarding both resistance and sensitivity. A score is generated on a scale from 0 to 100, where values closer to 100 indicate a high likelihood that the patient will have a beneficial response to the drug, and values closer to 0 suggest the patient is unlikely to respond well to the treatment.
The process taken from biopsy to score takes a total of 72 hours. This score is forwarded to the oncologist who then considers this very critical information when tailoring a specific treatment plan for the patient.
Check out the video below kindly provided by Allarity Therapeutics.
Increased pCR rate expected with Platin-DRP™
This interactive chart is a simulation using cisplatin in combination with PD-(L)1. It illustrates the connection between Platin-DRP™ scores and pCR rates (Pathologic Complete Response rate).
If the platin does not work, neither does the paired therapy (eg, the PD-(L)1). Using the Platin-DRP™, patients can be selected based on their likelihood to respond positively to platin-treatment. Patients included in the interactive graph represent those with the highest Platin-DRP™ scores.
By excluding those not sensitive to platin treatment, we spare them from the harsh side effects of chemotherapy, allowing them to move on to more effective treatments, and further improving the patients’ pCR rate.
Try using the sliding tool below. By selecting patients with a higher Platin-DRP™ score the pCR rate is increased.
The top % of Platin-DRP™ scored patients included represents the percentage of patients with the highest Platin-DRP™ score. For example, by including the top 33% Platin-DRP™ scores, 67% of patients with the lowest Platin-DRP™ scores are excluded.
Expected disease-specific survival based on a multivariable model in the ACV cohort of JBR.10. Curves shown for expected disease-specific survival based on the multivariate time-dependent model from JBR.10 with values of the combined profiles (DRP) of 10, 25, 50, 75 and 90 for a model including gender male, age 62 years, histology adenocarcinoma and stage 2
Interactive Histogram of % Top DRP Scored Patients Included
Cisplatin and Immunotherapy Treatment Today
Currently, 10-15% of all cancer patients receive cisplatin or one of its analogues. Combining cisplatin (or one of its analogues) with immunotherapy has significantly improved cancer survival rates. These synergistic effects have led to a notable rise in popularity in recent years.
PD-L1 and PD-1 inhibitors are popular immunotherapy drugs recognized for their versatility across various cancer types. These treatments block the interaction between programmed cell death protein 1 (PD-1) on immune cells and PD-L1 on tumor cells, which tumors use to evade immune detection. By inhibiting this pathway, PD-(L)1 drugs re-activate the immune system, allowing it to recognize and attack cancer cells. Cisplatin enhances this effect through its ability to induce immunogenic cell death, which complements the PD-(L)1 mechanism of action, making the combination therapy even more effective. Due to this synergy, approximately 50% of PD-(L)1 treatments today are administered alongside cisplatin or carboplatin.
Our Platin-DRP™ technology precisely identifies patients most likely to benefit from cisplatin, including in combination with PD-(L)1 immunotherapy. By filtering out patients with low Platin-DRP™ scores, the response rates for combination therapies increase significantly. This not only enhances treatment effectiveness but also minimizes patient suffering by guiding those with low Platin-DRP™ scores toward more suitable treatment options, potentially saving crucial time in their cancer journey.
With the PD-(L)1 inhibitor market projected to grow from USD $45.8 billion in 2023 to USD $105 billion by 2028, pharmaceutical companies must differentiate themselves in this rapidly growing, yet highly competitive market.
The Platin-DRP™ offers more personalized and effective treatments, helping companies differentiate themselves in an increasingly crowded space.
History of the Platin-DRP™
Professor Steen Knudsen, specializing in systems and molecular biology, advanced the understanding of how cancer cell lines in labs respond similarly to cancer in patients. This approach, linking drug sensitivity to tumor biology, was shared by CHOSA co-founder Peter Buhl Jensen and his collaborator Maxwell Sehested. Buhl and Sehested discovered that sensitivity and resistance patterns directly aligned with a drug’s mechanism of action.
From 2010, Knudsen and Jensen advanced DRP® technology together at Medical Prognosis Institute (MPI), in Copenhagen. In 2015, they co-founded Oncology Venture, focused on applying DRP® to select patients who would benefit from specific cancer treatments, while avoiding ineffective therapies.
Oncology Venture was founded by Peter Buhl Jensen, Ulla Hald Buhl, and Steen Knudsen, along with others. The company’s mission was to use the DRP® technology to guide the clinical development of cancer therapies. By pairing the right drug with the right patient, DRP® would enable precision medicine in oncology. Oncology Venture obtained the exclusive rights to license and commercialize DRP® technology, specifically focusing on its application in clinical oncology.
The Cisplatin Platin-DRP™ has a CE mark in the EU, which includes additional countries such as Norway, Lichtenstein, Turkey, Switzerland, Iceland. Additionally Platin-DRP™ has received an IDE approval with the FDA. These approvals demonstrate that the Platin-DRP™ is thoroughly validated.
The Platin-DRP™ has been clinically validated for cisplatin treatment in both breast and lung cancer through retrospective clinical studies. In addition, a prospective clinical study was completed and presented at ASCO in 2023, further supporting its predictive value. More recently, the Platin-DRP™ has also been validated for use in carboplatin-treated metastatic breast cancer patients, with results to be presented at ASCO.
LiPlaCis
In addition to our Platin-DRP™, we’re also developing a platinum-based drug named LiPlaCis. LiPlaCis is a cisplatin in a liposomal formulation, which allows the platinum-based treatment to target the tumor directly.
